Guggenheim Starts CRISPR Therapeutics (CRSP) at Buy
Tweet
Share
E-mailGet Alerts CRSP Hot Sheet
Price: $53.55 -0.81%
Rating Summary:
19 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
19 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Guggenheim initiated coverage on CRISPR Therapeutics (NASDAQ: CRSP) with a Buy rating and a price target of $30.00.
For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.
Shares of CRISPR Therapeutics closed at $17.50 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- Evercore ISI Starts Alvotech SA (ALVO) at Outperform
- Axis Capital Limited Assumes Jubilant Foodworks Ltd (JUBI:IN) at Reduce (3)
Create E-mail Alert Related Categories
New CoverageRelated Entities
GuggenheimSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
